Advances in laboratory medicine最新文献_第3页

Managing laboratory test ordering: a challenge in the new laboratory medicine model. 实验室测试订购管理：新实验室医学模式的挑战。

IF 1.1

Advances in laboratory medicine Pub Date : 2024-06-25 eCollection Date: 2024-09-01 DOI: 10.1515/almed-2024-0085

María Salinas, Ruth Torreblanca, Eduardo Sanchez, Álvaro Blasco, Emilio Flores, Maite López-Garrigós

{"title":"Managing laboratory test ordering: a challenge in the new laboratory medicine model.","authors":"María Salinas, Ruth Torreblanca, Eduardo Sanchez, Álvaro Blasco, Emilio Flores, Maite López-Garrigós","doi":"10.1515/almed-2024-0085","DOIUrl":"https://doi.org/10.1515/almed-2024-0085","url":null,"abstract":"Introduction: The role of Laboratory Medicine in patient care has evolved in the last decades. The same has occurred to the laboratory model, which has evolved from a traditional model where the laboratory is merely involved in clinical decision-making to a leading model where the laboratory is not only involved but also determines decision-making. The advent of new technologies and automation of processes have enabled laboratory professionals to focus on the first and last phase of the analytical process namely, test ordering and decision-making based on laboratory results. These phases are more error-prone than the analytical phase, and where action must be taken to improve the quality of patient care.Content: We share our experience in the design and establishment of laboratory test demand management interventions that facilitated diagnosis of occult disease, improved adherence to clinical guidelines, and optimized patient safety.Summary: A description is provided of key points in the management of laboratory test over/underutilization.Outlook: The objective of this review is to promote the involvement of laboratory professionals in the design and implementation of demand management interventions and in the development of the new Leader Laboratory model.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"236-247"},"PeriodicalIF":1.1,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interferencia del metamizol en la determinación de la concentración de creatinina sérica. 甲氰咪唑对测定血清肌酐浓度的干扰。

IF 1.1

Advances in laboratory medicine Pub Date : 2024-06-24 eCollection Date: 2024-09-01 DOI: 10.1515/almed-2024-0065

María-José Castro-Castro, Isabel Cachón-Suárez, Andrea Maestre-Fernández, Rosa Navarro-Badal

引用次数: 0

La gestión de la demanda de las pruebas: un reto en el nuevo modelo de medicina de laboratorio. 化验需求管理：化验医学新模式的挑战。

IF 1.1

Advances in laboratory medicine Pub Date : 2024-04-26 eCollection Date: 2024-09-01 DOI: 10.1515/almed-2023-0146

María Salinas, Ruth Torreblanca, Eduardo Sanchez, Álvaro Blasco, Emilio Flores, Maite López-Garrigós

引用次数: 0

Effects of antidiabetic drugs on bone metabolism. 抗糖尿病药物对骨代谢的影响。

Advances in laboratory medicine Pub Date : 2024-04-03 eCollection Date: 2024-03-01 DOI: 10.1515/almed-2024-0038

Nuria Padilla Apuntate, Carmen G Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza

{"title":"Effects of antidiabetic drugs on bone metabolism.","authors":"Nuria Padilla Apuntate, Carmen G Puerto Cabeza, Alba Gallego Royo, Nuria Goñi Ros, Claudia Abadía Molina, Javier Acha Pérez, Pilar Calmarza","doi":"10.1515/almed-2024-0038","DOIUrl":"https://doi.org/10.1515/almed-2024-0038","url":null,"abstract":"Objectives: The prevalence of diabetes mellitus type 2 (DMT2) is increasing exponentially worldwide. DMT2 patients have been found to be at a higher risk for bone fractures than the healthy population. Hence, improving our understanding of the impact of antidiabetic drugs on bone metabolism is crucial.Methods: A descriptive, retrospective study involving 106 patients receiving six groups of antidiabetic drugs: insulin; dipeptidylpeptidase four inhibitors (DPP4i); glucagon-like peptide type 1 receptor agonists (GLP1ra); sulfonylureas; sodium-glucose cotransporter two inhibitors (SGLT2i); and pioglitazone, in which osteocalcin (OC), bone alkaline phosphatase (BAP) and C-terminal telopeptide of collagen type 1 or beta-crosslaps (β-CTx) were determined.Results: β-CTx concentrations were higher in the patients treated with pioglitazone, as compared to patients treated with DPP4i (p=0.035), SGLT2i (p=0.020) or GLP1ra (p<0.001). The lowest β-CTx concentrations were observed in the patients treated with GLP1ra.Conclusions: Bone remodeling is influenced by the type of antidiabetic drug administered to DMT2 patients. In our study, the patients who received pioglitazone showed higher β-CTx concentrations, as compared to patients treated with other types of antidiabetic drugs. This finding highlights the convenience of avoiding these drugs, especially in postmenopausal women with DMT2. GLP1ra drugs were associated with the lowest β-CTx concentrations, which suggests that these agents could exert beneficial effects on bone metabolism.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 1","pages":"85-89"},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11019883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140856842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Compliance to specifications in an external quality assurance program: did new biological variation estimates of the European Federation of Laboratory Medicine (EFLM) affect the quality of laboratory results? 外部质量保证计划的规范遵守情况：欧洲实验室医学联合会（EFLM）新的生物变异估计值是否会影响实验室结果的质量？

Advances in laboratory medicine Pub Date : 2023-11-23 eCollection Date: 2023-12-01 DOI: 10.1515/almed-2023-0155

Carmen Ricós, Carmen Perich, Sandra Bullich, Montserrat Ventura, Berta Piqueras, Mariona Panadés, Pilar Fernández-Calle

{"title":"Compliance to specifications in an external quality assurance program: did new biological variation estimates of the European Federation of Laboratory Medicine (EFLM) affect the quality of laboratory results?","authors":"Carmen Ricós, Carmen Perich, Sandra Bullich, Montserrat Ventura, Berta Piqueras, Mariona Panadés, Pilar Fernández-Calle","doi":"10.1515/almed-2023-0155","DOIUrl":"https://doi.org/10.1515/almed-2023-0155","url":null,"abstract":"Objectives: The results of external quality assurance schemes are evaluated against specifications generally based on biological variation (BV) data. This study was carried out to determine whether new BV values affected the level of compliance to specifications. Our secondary objective was to identify the conditions that would be compromised as a result of poor analytical performance in disease associated markers.Methods: This study was based on the results of the SEQCML External Quality Assurance scheme for the 2015-2022 period. Deviation of the individual result from the target value was estimated. Additionally, we calculated the percentage of results that met the pre-established specification.Results: In 97 of the 133 analytes, the level of compliance was maintained in 80-90 % of the results obtained in the two study periods. In 23 analytes, the level of compliance ranged from 51 to 79 % in the two study periods. In ALT, AST and sodium, the level of compliance was ≤50 % of the results obtained in the first study period, with sodium being the only analyte that maintained this poor level of compliance in the second study period.Conclusions: The level of compliance to specifications remained independent from the specification used (SEQCML or EFLM) for the majority of the analytes. The results for sodium ion were below the target value, which may lead to misdiagnosis of hyponatremia. Non-compensated alkaline picrate methods overestimate creatinine, which may produce false information suggestive of kidney failure.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 4","pages":"379-386"},"PeriodicalIF":0.0,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724879/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimization of a rapid method for screening drugs in blood by liquid chromatography tandem mass spectrometry. 优化液相色谱串联质谱法快速筛查血液中药物的方法。

IF 1.1

Advances in laboratory medicine Pub Date : 2023-11-23 eCollection Date: 2023-12-01 DOI: 10.1515/almed-2023-0154

Alba M Rodrigo Valero, Oscar Quintela Jorge, Begoña Bravo Serrano, Sara Ayuso Tejedor

{"title":"Optimization of a rapid method for screening drugs in blood by liquid chromatography tandem mass spectrometry.","authors":"Alba M Rodrigo Valero, Oscar Quintela Jorge, Begoña Bravo Serrano, Sara Ayuso Tejedor","doi":"10.1515/almed-2023-0154","DOIUrl":"10.1515/almed-2023-0154","url":null,"abstract":"Objectives: In the recent years, liquid chromatography with tandem mass spectrometry has gained popularity in laboratories. This technique has a higher specificity, detects different analytes from a single specimen, measures analytes in distinct matrices, and substantially reduce analytical interference, with respect to immunoassay. The processing and preparation of biological samples are crucial in chromatography. Interferences in blood testing are usually caused by the presence of phospholipids and proteins. The main objective of this study was to improve analytical processes for drug screening by LC-MS/MS using a novel blood sample preparation method based on protein precipitation and removal of phospholipids.Methods: An evaluation was performed of a new method for the preparation of blood samples based on protein precipitation and removal of phospholipids by LC-Q-q-LIT.Results: Limit of detection, limit of quantification and measurement range were determined for 56 molecules. The results of 11 cases were compared with those obtained using standard blood collection methods and instruments.Conclusions: The novel blood preparation and testing method based on LC-Q-q-LIT, a more sensitive technique, has demonstrated to yield comparable results to traditional methods. In addition, this new technique reduces turnaround time and costs.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"4 4","pages":"365-371"},"PeriodicalIF":1.1,"publicationDate":"2023-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10724859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Diasorin Liaison^® calprotectin fecal assay adapted for pleural effusion 适用于胸腔积液的Diasorin Liaison®钙保护蛋白粪便试验的评价

Advances in laboratory medicine Pub Date : 2023-11-14 DOI: 10.1515/almed-2023-0106

Cristina de Paz Poves, Clara Barneo-Caragol, Ana Isabel Cillero Sánchez, Lucía Jimenez Mendiguchia, Covadonga Quirós Caso, María Moreno Rodríguez, Francisco J. López González, Mᵃ Belén Prieto García

{"title":"Evaluation of Diasorin Liaison® calprotectin fecal assay adapted for pleural effusion","authors":"Cristina de Paz Poves, Clara Barneo-Caragol, Ana Isabel Cillero Sánchez, Lucía Jimenez Mendiguchia, Covadonga Quirós Caso, María Moreno Rodríguez, Francisco J. López González, Mᵃ Belén Prieto García","doi":"10.1515/almed-2023-0106","DOIUrl":"https://doi.org/10.1515/almed-2023-0106","url":null,"abstract":"Abstract Objectives Calprotectin (CP) is a calcium and zinc binding protein that is widely measured on faecal samples but its determination in other biological fluids might be of interest. The aim of this work was to validate the measurement of CP in pleural fluid by chemiluminescence. Methods LIAISON ® XL, a fully automated chemiluminescence analyzer, was used for CP quantification on pleural fluid. A validation protocol was designed using both quality control materials provided by the manufacturer and pools of pleural fluid samples. Stability, imprecision, bias, linearity, detection capability and carry over effect were evaluated. Results CP was stable on pleural fluid at least one week, under refrigerated conditions, and four weeks at −80 °C. The observed intra- and inter-day imprecision was between 2.2 and 6.49 %, with a negative bias under 5.51 %. The linearity of the method was verified up to 2,000 ng/mL. The LoQ for the assay was 48.52 ng/mL. A statistically significant carry-over effect was observed after measuring CP concentrations above the upper limit of linearity, but given the observed magnitude, a clinically relevant impact should not be expected. Conclusions Diasorin Liaison ® calprotectin assay allows reliable measurement of CP in pleural fluid.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"7 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136229438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum biomarkers for liver fibrosis assessment 评估肝纤维化的血清生物标志物

Advances in laboratory medicine Pub Date : 2023-11-14 DOI: 10.1515/almed-2023-0081

Julia Maroto-García, Ana Moreno Álvarez, María P. Sanz de Pedro, Antonio Buño-Soto, Álvaro González

引用次数: 0

Novelties in the ISO 15189:2023 standard ISO 15189:2023标准中的新特性

Advances in laboratory medicine Pub Date : 2023-11-13 DOI: 10.1515/almed-2023-0139

Isabel de la Villa Porras

引用次数: 0

Calibration – an under-appreciated component in the analytical process of the medical laboratories 校准——医学实验室分析过程中一个未被充分重视的组成部分

Advances in laboratory medicine Pub Date : 2023-11-13 DOI: 10.1515/almed-2023-0127

Oswald Sonntag, Tze Ping Loh

引用次数: 0